Fehniger TA - Search Results

1

Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo.

Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA. Fehniger TA, et al. J Immunol. 2000 Feb 15;164(4):1643-7. doi: 10.4049/jimmunol.164.4.1643. J Immunol. 2000. PMID: 10657604

2

CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.

Carson WE, Fehniger TA, Caligiuri MA. Carson WE, et al. Among authors: fehniger ta. Eur J Immunol. 1997 Feb;27(2):354-60. doi: 10.1002/eji.1830270203. Eur J Immunol. 1997. PMID: 9045904

3

A potential role for interleukin-15 in the regulation of human natural killer cell survival.

Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA. Carson WE, et al. Among authors: fehniger ta. J Clin Invest. 1997 Mar 1;99(5):937-43. doi: 10.1172/JCI119258. J Clin Invest. 1997. PMID: 9062351 Free PMC article.

4

Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.

Fehniger TA, Carson WE, Mrózek E, Caligiuri MA. Fehniger TA, et al. Blood. 1997 Nov 1;90(9):3647-53. Blood. 1997. PMID: 9345049 Free article.

5

Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA. Khatri VP, et al. Among authors: fehniger ta. J Clin Invest. 1998 Mar 15;101(6):1373-8. doi: 10.1172/JCI2038. J Clin Invest. 1998. PMID: 9502779 Free PMC article.

6

Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.

Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA, Evans SS. Frey M, et al. Among authors: fehniger ta. J Immunol. 1998 Jul 1;161(1):400-8. J Immunol. 1998. PMID: 9647249

7

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Meropol NJ, et al. Among authors: fehniger ta. Cancer Immunol Immunother. 1998 Aug;46(6):318-26. doi: 10.1007/s002620050493. Cancer Immunol Immunother. 1998. PMID: 9756416 Free PMC article. Clinical Trial.

8

Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.

Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA. Yu H, et al. Among authors: fehniger ta. Blood. 1998 Nov 15;92(10):3647-57. Blood. 1998. PMID: 9808558 Free article.

9

Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.

Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, Caligiuri MA. Fehniger TA, et al. J Immunol. 1998 Dec 1;161(11):6433-8. J Immunol. 1998. PMID: 9834136

10

Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA. Fehniger TA, et al. J Immunol. 1999 Apr 15;162(8):4511-20. J Immunol. 1999. PMID: 10201989

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters